Up, down and up again. Here's what happened with the CSL share price in 2023

The CSL share price underperformed the ASX 200 in 2023 but had a very strong end to the year.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

2023 was a volatile year for the CSL Ltd (ASX: CSL) share price.

Investors who bought the S&P/ASX 200 Index (ASX: XJO) healthcare stock at the close of 2022 could have picked up shares for $287.76 apiece.

Slightly less than halfway through 2023, on 13 June, CSL finished the day trading for $308.52. That's a gain of 7.3%.

But things went south from there, with the CSL share price tumbling to $230.65 by market close on 30 October.

And then… it was up again, with the healthcare stock finishing 2023 trading for $286.65 a share.

That left the stock down 0.4% for the calendar year. Not including the dividends.

Over the course of the year, eligible investors also will have received $3.63 in partly franked dividends. If we add those back in, the accumulated value of CSL shares gained 0.8%.

Still, that's significantly less than the 9.3% gains posted by the ASX 200 in 2023. Gains which rise to some 13.9% if we add in the dividends delivered by income-paying stocks.

So, what went right and what went wrong during 2023?

What moved the CSL share price in 2023?

Things were ticking along well for CSL shareholders until the company provided a sobering market update on 14 June.

The gist of that update concerned a reduced profit forecast after sharper-than-expected foreign currency headwinds. CSL's prior forecast, delivered during its half-year results presentation, expected a foreign currency impact of US$175 million. On 14 June, the company raised those expectations to the range of US$230 million to US$250 million.

And with the company's FY 2024 profit guidance of US$2.9 billion to US$3 billion, at constant currency, coming in below consensus expectations, the CSL share price tumbled 6.9% on the day and 2.7% the following trading day.

But, as mentioned up top, things took a turn for the better after shares hit their 2023 lows on 30 October, gaining 24% by year's end.

That lift looks to have come from two fronts.

First, numerous brokers reported they believed the company was undervalued at current prices, expecting CSL to deliver higher profit margins in the year ahead.

Second, CSL held its capital markets day presentation in October, where the company's exploration of generative AI to enhance its operations may have stoked investor interest.

Management also highlighted that the company counts as the world's biggest in the $38 billion plasma protein therapies industry), and the second biggest in the $7 billion flu vaccines industry.

The CSL share price could have gotten some additional tailwinds in the last two months of 2023, with the company forecasting annual double-digit earnings growth.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »